Infectious Diseases News and Research

RSS

Canada's VSV-EBOV Ebola vaccine proves safe, effective in Phase 1 clinical trial

The Honourable Rona Ambrose, Minister of Health, and Canada's Chief Public Health Officer, Dr. Gregory Taylor, today welcomed the news of promising trial outcomes of Canada's VSV-EBOV Ebola vaccine. The results of several studies and trials bring the world closer to ending this global outbreak through the provision of a commercially available vaccine.

2 Apr 2015

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company’s investigational fully personalized immunotherapy for HIV.

2 Apr 2015

NIH awards $2.1 million grant to counter antibiotic resistance in Gram-negative bacteria

The National Institutes of Health has awarded Dr. Walter Fast, associate professor of medicinal chemistry at The University of Texas at Austin's College of Pharmacy, a four-year $2.1 million grant to develop small-molecules that counter antibiotic resistance in Gram-negative bacteria. If successful, the research could lead to new drugs for treating bacterial infections that are resistant to most antibiotics.

1 Apr 2015

Roche launches new protein melting application for real-time PCR LightCycler 1536 instrument

Roche announced today the introduction of a new protein melting application for its high-throughput, real-time PCR LightCycler 1536 instrument. The fully automated platform now allows life science researchers to perform thermal shift assays (TSAs) in 1536-well applications quickly and consistently.

From Roche Sequencing and Life Science 31 Mar 2015

New research reveals how a deadly fungus grows and kills immune cells

New research from the University of Toronto has scientists re-thinking how a lethal fungus grows and kills immune cells. The study hints at a new approach to therapy for Candida albicans, one of the most common causes of bloodstream infections.

31 Mar 2015

New HCV therapies cost-effective in specific groups of HCV-infected patients

A study led by Boston Medical Center researchers demonstrates that while new therapies to treat Hepatitis C Virus (HCV) are highly effective, they are cost-effective and provide the greatest value in specific groups of HCV-infected patients.

31 Mar 2015

Compact MRI and multimodality: an interview with Bernard Siow, UCL

CABI is a preclinical imaging laboratory where we have about ten modalities. We started off with MRI and we have a 9.4T high-field system.

From Bruker BioSpin Division 30 Mar 2015

Study provides insights into climate, social factors that trigger dengue outbreaks

Researchers at Upstate Medical University, in collaboration with a team of international investigators studying dengue fever, have discovered new information on climate drivers of the disease and social risk factors that may be contributing to its spread, according to two scientific papers recently published in BMC Infectious Disease and BMC Public Health, open access, peer-reviewed online journals.

30 Mar 2015

Study finds link between neurodegenerative disorders and inflammation

Researchers from McMaster University and the Icahn School of Medicine at Mount Sinai, New York have discovered that a protein associated with neurodegenerative diseases like ALS also plays an important role in the body's natural antiviral response.

30 Mar 2015

Effective therapy enables immune system recovery in majority of children

Most children with HIV who have low levels of a key immune cell eventually recover levels of this cell after they begin treatment, according to a new study conducted by researchers at UCLA and other institutions in the U.S. and Brazil.

30 Mar 2015

Naldemedine meets primary and secondary endpoints in phase III study for OIC treatment

Naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA) under development by Shionogi & Co., Ltd., met its primary and secondary endpoints in a phase III study (COMPOSE I) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain receiving opioid therapy.

30 Mar 2015

Rare genetic mutation explains why flu can kill in rare cases

Nobody likes getting the flu, but for some people, fluids and rest aren't enough. A small number of children who catch the influenza virus fall so ill they end up in the hospital — perhaps needing ventilators to breathe — even while their family and friends recover easily. New research by Rockefeller University scientists, published March 26 in Science, helps explain why: a rare genetic mutation.

30 Mar 2015

Experimental nanoparticle therapy speeds healing of all sorts of wounds

An experimental therapy developed by researchers at Albert Einstein College of Medicine of Yeshiva University cut in half the time it takes to heal wounds compared to no treatment at all. Details of the therapy, which was successfully tested in mice, were published online in the Journal of Investigative Dermatology.

30 Mar 2015

Study suggests new approach to help prevent meningococcal outbreaks

Nasal drops of harmless bacteria can inhibit a related bug that sometimes causes meningococcal disease, according to new findings published online in Clinical Infectious Diseases. The study--conducted among college students, a group at higher risk for this often serious illness--suggests a new approach that could help suppress outbreaks of the disease, if supported by future research.

30 Mar 2015

Research: Common bacteria poised to become antibiotic-resistant superbugs

Antibiotic resistance is poised to spread globally among bacteria frequently implicated in respiratory and urinary infections in hospital settings, according to new research at Washington University School of Medicine in St. Louis.

30 Mar 2015

Two experimental Ebola vaccines appear to be safe in PREVAIL clinical trial in Liberia

Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase 2/3 clinical trial, according to interim findings from an independent Data and Safety Monitoring Board review.

30 Mar 2015

Study finds C. difficile infection increases hospital readmission rates

Patients with Clostridium difficile infection (CDI) are twice as likely to be readmitted to the hospital as patients without the deadly diarrheal infection, according to a study published in the April issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology.

30 Mar 2015

Promising clinical trial results for ebola vaccines

Interim findings from a clinical trial (PREVAIL) in which two experimental Ebola vaccines were given to more than 600 people in Liberia indicate that the vaccines are safe for use in humans. Based on these positive results, the vaccines may continue into the next stage of clinical evaluation; a phase 3 trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

27 Mar 2015

New Ebola vaccine shows promise in first phase 1 clinical trial

Results from the first phase 1 trial of an Ebola vaccine based on the current (2014) strain of the virus are today published in The Lancet. Until now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. The results suggest that the new vaccine is safe, and provokes an immune response in recipients, although further long-term testing will be needed to establish whether it can protect against the Ebola virus.

27 Mar 2015

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia.

26 Mar 2015

Infectious Diseases News and Research

Canada's VSV-EBOV Ebola vaccine proves safe, effective in Phase 1 clinical trial

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

NIH awards $2.1 million grant to counter antibiotic resistance in Gram-negative bacteria

Roche launches new protein melting application for real-time PCR LightCycler 1536 instrument

New research reveals how a deadly fungus grows and kills immune cells

New HCV therapies cost-effective in specific groups of HCV-infected patients

Compact MRI and multimodality: an interview with Bernard Siow, UCL

Study provides insights into climate, social factors that trigger dengue outbreaks

Study finds link between neurodegenerative disorders and inflammation

Effective therapy enables immune system recovery in majority of children

Naldemedine meets primary and secondary endpoints in phase III study for OIC treatment

Rare genetic mutation explains why flu can kill in rare cases

Experimental nanoparticle therapy speeds healing of all sorts of wounds

Study suggests new approach to help prevent meningococcal outbreaks

Research: Common bacteria poised to become antibiotic-resistant superbugs

Two experimental Ebola vaccines appear to be safe in PREVAIL clinical trial in Liberia

Study finds C. difficile infection increases hospital readmission rates

Promising clinical trial results for ebola vaccines

New Ebola vaccine shows promise in first phase 1 clinical trial

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Industry Focus eBook - Infectious Diseases (3rd Edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News